Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint(R)'s ability to predict response to neoadjuvant chemotherapy in breast cancer. Â*Â*Â* Dr. Laura van 't Veer, from the Netherlands Cancer Institute, presented the data at the 2008 San Antonio Breast Cancer Symposium (SABCS) during the session Molecular profiling for guiding therapeutic decisions.
More...